The conference came at an exciting time for oncology, just a week after the historic FDA approval of the first CAR-T therapy in which a patient’s immune cells are removed from their body, genetically engineered to attack specific cancer cells and then infused back to the patient.  Dr. Levine addressed the ethical challenges associated with bringing these powerful but highly toxic therapies to market and identified pitfalls to watch for and strategies to use to help the field develop ethically and efficiently.